Engineering Nanoscale Exosomes for Lysosomal Delivery of Bioactive Enzymes by Do, Mai Anh
Santa Clara University
Scholar Commons
Bioengineering Master's Theses Engineering Master's Theses
6-2018
Engineering Nanoscale Exosomes for Lysosomal
Delivery of Bioactive Enzymes
Mai Anh Do
Santa Clara University, mdo@scu.edu
Follow this and additional works at: https://scholarcommons.scu.edu/bioe_mstr
Part of the Biomedical Engineering and Bioengineering Commons
This Thesis is brought to you for free and open access by the Engineering Master's Theses at Scholar Commons. It has been accepted for inclusion in
Bioengineering Master's Theses by an authorized administrator of Scholar Commons. For more information, please contact rscroggin@scu.edu.
Recommended Citation
Do, Mai Anh, "Engineering Nanoscale Exosomes for Lysosomal Delivery of Bioactive Enzymes" (2018). Bioengineering Master's Theses.
3.
https://scholarcommons.scu.edu/bioe_mstr/3

ii 	
 
 
 
 
Engineering Nanoscale Exosomes for Lysosomal 
Delivery of Bioactive Enzymes 
 
 
By 
 
Mai Anh Do 
 
 
 
 
Master’s Thesis 
 
 
 
Submitted to 
the Department of Bioengineering 
of 
SANTA CLARA UNIVERSITY 
 
in Partial Fulfillment of the Requirements 
for the degree of 
Master’s of Science in Bioengineering 
 
 
Santa Clara, California 
 
 
2018 
iii 	
ACKNOWLEDGEMENTS 
 
I would like to thank my thesis advisor Dr. Biao Lu of the Department of Bioengineering at 
Santa Clara University for all his insight, guidance, and support over the past two years. I could 
not have asked for a better mentor for my Master’s study.  
 
Next, I would like to thank Daniel Levy for tirelessly working by my side throughout the project. 
His dedication helped me in carrying out this work.  
 
Additionally, I would like to extend my deepest thanks to Adrian Valones and Matthew Blanco 
for going above and beyond to ensure smooth administrative processing over the two years.  
 
Finally, I would like to thank David Nguyen for all his love and support throughout this journey.  
 
 
	  
iii 	
DISLOSURE 
 
This is a joint study of Mai Anh Do and Daniel Levy. Data overlap between the two submitted 
theses.  
 
Figure 1 prepared by Dr. Biao Lu. 
Figure 2, 4, 8-9 prepared by Mai Anh Do. 
Figure 3, 5-7 prepared by Daniel Levy.  
Figure captions were written on individual basis.  
 
  
 
This work was supported in part by an internal grant of the Department of Engineering at SCU. 
 
	
	
4 	
Engineering Nanoscale Exosomes for Lysosomal Delivery 
of Bioactive Enzymes 
 
Mai Anh Do 
Department of Bioengineering 
Santa Clara University 
2018 
 
 
 
 
ABSTRACT 
 
 
 
There are at least 50 lysosomal storage diseases that are caused by accumulation of a substrate due 
to a defective enzyme. Although some treatment options are available, low efficacy, high cost, and 
immunogenicity are main challenges of current treatments. To overcome those limitations, we use 
cell-derived nanoparticles to deliver biologically active cargos into lysosomes. Naturally produced 
exosomes can deliver proteins without triggering an immune response. Additionally, exosome have 
an intrinsic ability to cross blood brain barrier benefiting patients at a late disease stage that affects 
the brain. After fusing either Gaussia luciferase (gLuc) or puromycin resistant protein (puro) onto a 
vesicular stomatitis virus glycoprotein (VSVG) with GFP/RFP reporters, we show that exosomes 
can be loaded with the recombinant protein without changing basic characteristics of exosomes. 
Moreover, we show that the biological activity of the proteins is retained in both the producer and 
recipient cells at a statistically significant level. As expected, the modified exosomes co-localize 
with both lysosomal and endosomal compartments indicating that they still undergo an endosomal 
pathway after an uptake assay. This work demonstrates that we can engineer nanoscale exosomes 
for delivery of therapeutic enzymes into lysosomes. The engineered vesicles have a great potential 
of becoming a method for enzyme delivery into patients with a lysosomal storage disease.  
5 	
TABLE OF CONTENTS 
	
INTRODUCTION 6 
1.1 Background 6 
1.2 Current Technologies and Motivation 6 
1.3 Project Goals 7 
MATERIALS AND METHODS 8 
2.1 Design and Construction of VSVG Fusion Proteins 8 
2.2 Cell Culture and Transfection 9 
2.3 Live Cell and Exosome Microscopy 9 
2.4 Exosome Preparation and Isolation 9 
2.5 Drug Selection and Stable Cell Line Establishment 9 
2.6 Luciferase Activity Assay 10 
2.7 Exosome Uptake Assay 10 
2.8 HOECHST Staining 10 
2.9 Western Blot 10 
2.10 Dot Blot 11 
2.11 ELISA 11 
2.12 Nanoparticle Tracking Analysis 11 
2.13 Lysosomal Staining 11 
2.14 Endosomal Staining 11 
2.15 Cell Counting 12 
RESULTS 13 
3.1 Results 13 
3.2 Discussion 20 
CONCLUSION 22 
REFERENCES 23 
LIST OF FIGURES 27 
6 	
 
 
INTRODUCTION 
 
1.1 Background 
 
Delivery of therapeutic proteins into cells is challenging although protein drugs have been widely 
used since the late 20th century.1 Moreover, there are limitations to the therapeutics due to protein 
instability, immunogenicity, low bioavailability or specificity.1,2   
 
There are approximately 50 different lysosomal storage diseases3,4 caused by lysosomal enzymes 
that are either missing or expressed at a very low level. The inefficient level of enzymes leads to 
accumulation of substrates which can have a downstream effect on the cell pathology.4 Gaucher’s, 
Tay-Sachs, and Salla disease are examples of lysosomal storage diseases that exhibit different 
debilitating forms in infants, juveniles and adults.5 There are many approaches to treat lysosomal 
storage diseases such as enzyme replacement therapy or substrate reduction therapy6. In this work, 
we will focus on a new approach that takes advantage of cell-derived nanoparticles called 
exosomes to deliver therapeutic proteins into cells.  
 
Exosomes are nanovesicles ranging between 30-150 nm in diameter. They are composed of a 
phospholipid bilayer membrane similar to a plasma membrane. Exosomes are naturally produced, 
loaded, and secreted by all human cells.7,8 Exosome production starts with invagination of plasma 
membrane to form an intracellular compartment called endosome.9 When endosomal membrane 
undergoes another round of invagination, smaller intraluminal vesicles are formed (Fig. 1C). An 
endosome containing multiple intraluminal vesicles is called a multivesicular body (MVB) as seen 
in Figure 1C. Usually, the MVB then fuses back with the plasma membrane releasing the content 
into the extracellular space. Once released, the intraluminal vesicles are called exosomes.9 Another 
pathway for MVB is through fusion with lysosome where the released content is either destroyed10 
or used as a potential enzyme replacement. The primary purpose of exosomes is cell 
communication since the exosomal lumen is loaded with cytoplasmic content of the producer cell 
during formation.9,10,11 Different RNA and protein cargos are delivered after exosomes are 
endocytosed into a recipient cell as shown in Figure 1D. During this process, exosomes end up 
back in the endosomal compartment where they either fuse back and release the content to the 
cytoplasm, or are delivered into lysosomes.9 Since exosomes are produced naturally by our cells, 
they have a greater potential of delivering drugs without triggering immune response compared to 
synthetic nanoparticles. Many attempts of using exosomal pathway for drug delivery have been 
made. Exosomes have been shown to successfully deliver siRNAs both in vitro and in vivo12,13. 
They can also be loaded with proteins, lipids, and DNA14,15 which demonstrates their immense 
potential.    
 
1.2 Current Technologies and Motivation 
 
Currently, there are several available treatments for lysosomal storage diseases, however, the 
technologies are very limited due to low efficacy, high cost, or impracticability. One possible 
strategy is a bone marrow transplantation16 that uses hematopoietic progenitor cells to produce the 
missing enzyme. This treatment is, however, only possible for young children under three years 
old with an available donor,6,17 which makes most of the lysosomal storage disease patients 
ineligible. Another strategy is an enzyme replacement therapy18,19 where patients are given an 
infusion with functional enzyme, however, the bioavailability of most enzymes is very low which 
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leads to repeated infusions. Moreover, naked enzymes do not have the ability to cross a blood 
brain barrier, and thus, the therapy is limited to patients without mental retardation. In substrate 
reduction therapy, it is required that the patient has residual enzyme activity, which makes the 
treatment unsuitable for patients with zero active enzyme level.20,21,22 If a patient produces the 
required enzyme in a misfolded form, chemical chaperone therapy23,24,25 can be used to stabilize 
the enzyme. Again, this therapy is limited because only patients with minimal enzyme expression 
can undergo the treatment. In the recent years, gene therapy18,26 for lysosomal storage diseases 
started to be explored. Nonetheless, the treatment is expensive and not effective in all patients. 
Gene therapy for a lysosomal storage disease of the central nervous system is also not well 
understood.6   
   
Low bioavailability, impracticality, and inability to surpass blood brain barrier are the main 
limitations of current treatments. Recent studies have yielded new strategies for overcoming the 
current drawbacks by using nanoparticles to deliver missing proteins into lysosome.27 
Nanoparticles can provide targeted drug delivery, improve drug stability, and reduce side effect.28 
However, most nanoparticles are synthetic, therefore, there is a great chance of triggering patient’s 
immune system even with immunosuppression treatment.28  
 
In this study, we use cell-derived nanoparticles to deliver missing bioactive enzymes into 
lysosomes. Exosomes have the ability to be loaded with any protein, shuttle it from a producer to 
recipient cell, and eventually unload the cargo into lysosome. Since exosomes are naturally 
produced by human cells, there is very low probability of immune response. Moreover, exosomes 
have an innate ability to cross a blood brain barrier, therefore, making it possible to treat all stages 
of lysosomal storage diseases. Exosomes could also be engineered to deliver drugs into targeted 
tissue by changing the outer membrane profile.  
 
To load our therapeutic protein into exosomes, we use an anchoring transmembrane protein. The 
most common membrane proteins for extracellular vesicles including exosomes are CD63, CD81, 
and CD9.29 These tetraspanins have cytoplasmic, transmembrane, as well as extracellular domains, 
making them potentially good anchors for the cargo. However, loading onto these proteins can be 
quite challenging because of the size and structure of the proteins. Here, we use vesicular 
stomatitis virus glycoprotein (VSVG) that contains the same domains as the CD proteins but 
VSVG penetrates the membrane only once. Additionally, it is has been shown that this viral 
envelope protein increases the loading ability of the cargo during transfection30,31 with exception 
to some immune cells.32 VSVG has been approved for various clinical trials due to its high 
efficacy.30 Here, we fuse VSVG with Gaussia luciferase (gLuc) enzyme due to its simple and 
robust activity assay.33,34 In addition to the therapeutic protein, we also attach GFP or RFP as 
visual reporters for tracking and analysis.  
 
1.3 Project Goals 
 
To deliver biologically active proteins into lysosome using exosomes, we have a four-fold 
objective. First, we have to design and engineer the DNA vector containing a fusion of VSVG, 
protein of interest (gLuc or puro), and visual reporters (GFP or RFP). Next, we transfect the 
constructs in the cells to track the expression and production of the fusion proteins in the 
intraluminal vesicles. Third, we characterize exosomes outside the cell and show biological 
activity. Lastly, we deliver the cargo-containing exosomes into recipient cells and show co-
localization with lysosome, as well as retained biological activity.  
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MATERIALS AND METHODS 
 
2.1 Design and Construction of VSVG Fusion Proteins 
 
The expression vector for the VSVG fusion protein contains a CMV promoter, VSVG coding 
sequence, GFP or RFP coding sequence, Gaussia Luciferase (gLuc) or Puromycin resistance gene 
sequence (puro), and a polyA signal as shown in Figure 1A. All sequences were attached on the C-
terminus of VSVG which allowed for loading the cargo proteins into the exosomes as shown in 
Figure 1B. The construction and DNA sequencing of the vector was carried out at GenScript, CA, 
USA. In this paper, GFP/RFP will be referred as reporter, while puro/gLuc as cargo.  
 
 
 
Figure 1. Design and construction of dual tagged reporter protein for exosome tracking. 
(A) Vector design for VSVG fusion proteins. Fluorescent (GFP, RFP) and activity (gLuc, puro) reporter genes were 
respectively attached at the C-terminus. (B) The schematic of dual loaded exosomes showing VSVG (black) 
transmembrane protein, GFP (green) or RFP (red) reporters, and gLuc (brown) or Puro (purple) protein cargos. (C) 
Illustration of VSVG-exosome biogenesis. Expressed VSVG-reporter-cargo construct is transferred to plasma 
membrane. Inward budding of the VSVG-reporter-cargo enriched plasma membrane creates endosomes. Once 
endosomes are formed, exosomes are generated by inward budding of the endosomal membrane. At the late-endosome 
stage, multivesicular body (MVB) fuses with plasma membrane resulting in exosome release into extracellular space. 
(D) Proposed exosome uptake model. Cells incorporate extracellular exosomes into the endosomes through 
endocytosis. Then, the endosomes unload the cargo at a final destination (lysosome). 
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2.2 Cell Culture and Transfection  
 
HEK293 cells (Alstem, CA, USA) were cultured in Dulbecco's Minimal Essential Medium 
(DMEM) (Gibco, MA, USA) supplemented with 10% fetal bovine serum (FBS) (GE Healthcare 
Life Sciences, PA, USA) and 1% Penicillin Streptomycin (Pen Strep) (Gibco, MA, USA). Human 
hepatocellular carcinoma cells (HEPG2), human glioblastoma cells (U87), and mouse adipose 
tissue fibroblast cells (L929) were purchased from American Type Culture Collection (VA, USA) 
and cultured under the same condition. All cells were maintained at 37°C with 5% CO2 in 
humidified air. At ~80 % confluence, cells were passaged using 0.25% trypsin-
ethylenediamnietraacetic acid (trypsin-EDTA) (Gibco, MA, USA) for cell dissociation.  
At 40, 50, or 60% confluence, cells were transfected in a 6-well plate using plasmid DNA (2 
µg/well) and 10 µl polyethylenimine (PEI) transfection reagent. DNA and PEI were each diluted 
in 100 µl of reduced serum media Opti-Mem (Gibco, MA, USA) and mixed. Transfection 
complex was incubated for 20 min then added into cell culture. For co-transfection, 1 µg of each 
DNA was used per well. For exosome preparation, 20 µg of DNA, 100 µL of PEI, and 2 ml of 
Opti-Mem was used per 145mm culture dish. 
 
2.3 Live Cell and Exosome Microscopy  
  
Live cell or exosome images were taken using a Lumen Dynamics x-cite 120LED Olympus 
CKX53 fluorescent microscope and processed through Olympus cellSens Standard software. 
Leica TCS SP8 confocal laser scanning microscope and Las X software were used to capture and 
process confocal images. Images of the same field were taken under phase contrast, and GFP 
and/or RFP settings at 20x or 40x magnification. Pictures were overlaid using GIMP 2.8.22 
software to show GFP and/or RFP location.  
 
 
2.4 Exosome Preparation and Isolation 
  
DMEM (+10% FBS and 1% PenStrep) media change to serum free UltraCulture (Lonza, 
Switzerland) was done on HEK293 day one post transfection or two days post stable cell line 
passage. After 48 hours, conditioned culture media was collected from 145 mm culture dishes and 
centrifuged for 10 min at 1500g. The supernatant was then filtered through a 0.2 µm 
polyethersulfone membrane filter (VWR, PA, USA). Exosomes were precipitated from the 
supernatant by adding ExoQuick-TC (System Biosciences, Inc., CA, USA) in 1:4 ratio, and 
incubated overnight at 4°C. Exosomes were collected by centrifuging at 3000g for 1.5 h. The 
pellet was resuspended in 150-300 µL PBS and final concentration was determined using 
NanoDrop Lite (Thermo Fisher Scientific, CA, USA). Purified exosomes were kept in 4°C for 
immediate use or stored at -20°C for future use. 
 
 
2.5 Drug Selection and Stable Cell Line Establishment  
 
24 h post transfection, HEK293 cells were treated with 5 µg/ml puromycin dihydrochloride 
(Thermo Fisher Scientific, CA, USA) in DMEM (+10% FBS and 1% PenStrep). Puromycin media 
was regularly changed until cells became stable. Stable cell line was established when cells 
appeared healthy, attached, and GFP/RFP-positive 65 days post puromycin treatment. Cells were 
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kept without puromycin pressure for at least one week before conducting further experiments.    
 
2.6 Luciferase Activity Assay  
 
500 µL (30 µL) of 1x Reporter Lysis Buffer (Promega, WI, USA) per well was used to lyse cells 
in a 6-well (96-well) plate 24 and/or 48 h post transfection, or 3, 8, 24, 48, 72 h post exosome 
uptake. 20 µL of lysed cells or purified exosomes was used per 100 µL of coelenterazine 
Gaussia luciferase substrate. The assay was performed in a white flat bottom 96-well plate without 
cover. Luminescence was measured on a TECAN infinite M200PRO plate reader using TECAN i-
control 1.8 software with 10 s exposure time.  
 
 
2.7 Exosome Uptake Assay  
 
HEK293, U87, L929 cells were cultured in a 96-well plate or a 4-chamber glass bottom plate until 
they reached 70 % confluence. Exosome dilution of 0.3 µg/µl in serum free UltraCulture (Lonza, 
Switzerland) was prepared and media change was performed on the day of uptake assay. For 
VSVG-GFP-gLuc or VSVG-RFP-gLuc exosomes, cells were washed 3x with pre-warmed PBS 
before lysing with 1x Reporter Lysis Buffer (Promega, WI, USA). Imaging or luciferase assay was 
followed at corresponding time points.  
 
2.8 HOECHST Staining  
 
1 mg/mL of Hoechst 33342 Stain (Thermo Fisher Scientific, IL, USA) solution was prepared in 
PBS. Media change was performed using the stain solution diluted 1:1000 in PBS. Plates were 
covered in aluminum foil and incubated for 10 min at 37°C with 5% CO2 in humidified air. Cells 
were washed 1x using pre-warmed PBS. Cells were kept in PBS for imaging using confocal 
microscopy.  
 
  
2.9 Western Blot  
 
15 or 60 µg of each exosome construct was reduced with 3x SDS sample buffer (New England 
BioLabs, MA, USA) containing of 0.1 M DTT reducing reagent in 2:1 ratio and then incubated for 
5 min at 90 °C water bath. All samples and 7 µL of Prestained Protein MW Marker #26612 
(Thermo Fisher Scientific, CA, USA) were then loaded into each well of a 4-12% ExpressPlus 
PAGE gel (GenScript USA Inc, NJ, USA). Electrophoresis was run for 1 h at 100 V. After 
electrophoresis, the gel and two sheets of filter blotting paper (ThermoFisher Scientific, CA, USA) 
were incubated at RT in diH2O for 10 min, followed by incubation at RT in 25mM tris/192mM 
glycine transfer buffer (BioRad, CA, USA) containing 20 % lab grade methanol (Fisher Science 
Education, PA, USA). Amersham Hybond P 0.2 um PVDF membrane (GE Healthcare Life 
Sciences, CA, USA) was activated by incubation in methanol for 20 s, diH2O for 20 s, and then 
transfer buffer for 10 min. Proteins were transferred onto the membrane using  
a semi-dry transfer cell (Bio-Rad, CA, USA). The transfer was run at 12 V for 12 min. The 
membrane was then incubated in 5 % non-fat dry milk (LabScientific, NJ, USA) 1x TBST pH 7.6 
(TEKNOVA, CA, USA) blocking buffer for 1 h at RT rocking. The membrane was then incubated 
in CD81 (Santa Cruz Biotechnology, CA, USA) or CD9 (abcam, Cambridge, UK) monoclonal 
mouse primary antibodies in a 1:500 ratio in blocking buffer. CD63 and HSP70 monoclonal rabbit 
antibodies (System Biosciences, CA, USA) were used in 1:1000 ratio. The overnight incubation 
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was carried at 5°C rocking. Following the primary incubation, the membrane was washed 3 x with 
1X TBST for 5 min. The goat anti-mouse (Thermo Fisher Scientific, IL, USA) or anti-rabbit 
(System Biosciences, CA, USA) HRP-conjugate secondary antibody was diluted 1: 2,500 and 1: 
10,000 in blocking buffer and membrane was incubated for 1 h at RT rocking. The membrane was 
washed 3 x with 1X TBST for 5 min before visualization. Part I and II of Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific, CA, USA) were mixed in 1:1 ratio and the 
membrane was incubated in the substrate solution for 1 min at RT rocking. The membrane was 
transferred into a plastic wrap and visualized using the ImageQuant LAS 500 (GE Healthcare Life 
Sciences, CA, USA) under chemiluminescence setting and 1 h exposure. 
 
2.10 Dot Blot 
 
250 µg of harvested VSVG-RFP-gLuc and VSVG-RFP-puro exosomes were sent to System 
BioSciences, CA, USA for Dot Blot Analysis.  
 
2.11 ELISA  
 
ExoELISA-ULTRA protein standard (System Biosciences, CA, USA) was used to establish a 
protein standard curve. Exosome samples were diluted to 120 µL with Coating Buffer (System 
Biosciences, CA, USA). 50 µg of exosomes was used per each ExoELISA micro-titer plate 
(System Biosciences, CA, USA) well. The plate was sealed and incubated at 37 °C for 1h. The 
plate was washed 3x for 5 min each with 100 µL of Wash Buffer (System Biosciences, CA, USA). 
50 µL of CD63 primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 
1:100 in Blocking Buffer (System Biosciences, CA, USA) was added to each well. The plate was 
incubated at RT for 1 h shaking followed by 3x wash for 5 min each with 100 µL of Wash Buffer. 
50 µL of secondary antibody diluted 1:5,000 in Blocking Buffer (System Biosciences, CA, USA) 
was added to each well. The plate was incubated at RT for 1 h shaking followed by 3x wash for 5 
min each with 100 µL of Wash Buffer. Next, 50 µL of Super-sensitive TMB ELISA substrate 
(System Biosciences, CA, USA) was added to each well and the plate was incubated at RT for 15 
min shaking. Finally, 50 µL of Stop buffer (System Biosciences, Palo Alto, CA, USA) was added 
followed by immediate quantitation using spectrophotometric plate reader at 450 nm.  
 
2.12 Nanoparticle Tracking Analysis  
 
Approximately 150 µL of 3-4 µg/µL harvested exosomes from all constructs and plain HEK293 
cells were sent to Particle Characterization Laboratories, Inc. Novato, USA for NTA analysis.  
 
2.13 Lysosomal Staining  
 
LysoTracker Red DND-99 (Invitrogen, Oregon, USA) stain was diluted in DMEM media to the 
final concentration of 75 nM. Media was changed to the pre-warmed staining solution and cells 
were incubated for 30 min at 37°C with 5% CO2 in humidified air. Media change to regular 
DMEM was performed before imaging cells using confocal microscopy.   
 
2.14 Endosomal Staining  
 
10 µL of either CellLight Early Endosomes-RFP (Invitrogen, Oregon, USA) or CellLight Late 
Endosome-RFP (Invitrogen, Oregon, USA) stain was added into HEK293 cells 48 hours after 
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VSVG-GFP-puro exosome uptake. The cells were incubated in the staining solution for 16 hours 
at 37°C with 5% CO2 in humidified air, and visualized using confocal microscope. Staining was 
performed in a 96-well plate.  
 
2.15 Cell Counting  
 
Cell counting was performed on cells treated with modified exosomes for 48h and puromycin for 
additional 48h. Cell media from each well of a 96-well plate was collected into separate 1.5ml 
microcentrifuge tubes. Cells were detached using 25 µL of 0.25% trypsin-EDTA (Gibco, MA, 
USA) and collected in the same microcentrifuge tubes. Cells were centrifuged at 1500x g for 5 
min and re-suspended in 100 µL of DMEM (+10% FBS and 1% PenStrep). 1:1 ratio of cell 
suspension to Tryphan Blue 0.4% Solution (MP Biomedicals, LLC, Ohio, USA) was mixed. Cells 
were then counted on a C-Chip Hemocytometer (INCYTO Co., Ltd., Convington, GA) under a 
Vista Vision light microscope (VWR, Brisbane, CA).  
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RESULTS 
 
3.1 Results 
 
Intracellular Tracking of VSVG Constructs in HEK293 Cells 
 
After HEK293 cell transfection with VSVG constructs, cells were tracked at three time points. 
Starting 24 hours post transfection, formed intraluminal vesicles (exosomes) contained the 
engineered VSVG-reporter-cargo constructs as indicated by the punctuated morphology. The 
modified-exosome containing cells were tracked again 48 and 72 hours (Fig. 2) post transfection. 
As predicted, the morphology of the intraluminal vesicles from all constructs did not change with 
time, which was compared to the morphology of cytosolic GFP that was evenly distributed 
throughout the cell.  
 
	
	
Figure 2. Intracellular tracking of exosome biogenesis. 
Formation of modified exosomes in HEK293 cells was tracked at 24 (not shown), 48 (not shown), and 72 hours (A-D) 
post PEI transfection. All 4 VSVG-reporter-cargo constructs showed punctuated formation of exosomes (A-D) 
compared to the disperse cytosolic GFP control (E). Negative control (not shown) had no color expression detected. 
Images were taken at 20x magnification using fluorescent microscope, then overlaid in GIMP software.  
	
Following transfection, a co-transfection experiment with exosomal markers CD63 and XPACK 
further showed that the engineered constructs go to exosomes. As Figure 3 demonstrates, the 
VSVG-RFP-gLuc construct co-localized with both CD63-GFP and XPACK-GFP which was 
clearly demonstrated by the yellow color in the overlaid pictures (arrows in Fig. 3A, 3C). The same 
was achieved for the VSVG-RFP-puro construct (Fig. 3B, 3D).      
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Figure 3. Colocalization of tracking molecules with exosome markers. 
PEI co-transfection of VSVG-RFP-cargo and CD63-GFP exosome marker (A-B) in HEK293 cells showed 
colocalization of the constructs (yellow). The same trend was observed when the experiment was repeated with 
XPACK-GFP exosome marker (C-D). All plasmids were co-transfected in 1:1 ratio. Images were taken at 20x 
magnification using fluorescent microscope at 48 (not shown) and 72 hours (A-D) post co-transfection.  
 
 
Biological Activity of the Cargo in the Producer Cells  
 
For both VSVG-GFP-gLuc and VSVG-RFP-gLuc transfected HEK293 cells, a Gaussia luciferase 
assay was performed on a cell lysate to show biological activity of the gLuc enzyme in the 
intracellular exosomes. 72 hours post transfection, cells containing VSVG-GFP-gLuc modified 
exosomes had a statistically significant 70.3-fold increase in enzymatic activity (Fig. 4A, second 
bar) compared to unmodified HEK293 cell lysate (Fig. 4A, first bar).  The VSVG-RFP-gLuc 
intracellular exosomes produced a statistically significant 90.4-fold increase in the same enzymatic 
assay (Fig. 4A, third bar), which demonstrated the retained activity of the gLuc cargo. To test the 
cargo activity in the VSVG-GFP-puro and VSVG-RFP-puro modified exosomes, the transfected 
HEK293 cells underwent a 5 µg/ml puromycin treatment. Images taken 24 hours post treatment 
show that most cells were still attached and resistant to puromycin, indicating the puromycin 
resistant gene was still biologically active for both VSVG-GFP-puro and VSVG-RFP-puro 
constructs (Fig. 4B) after being loaded into exosomes.  
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Figure 4. Engineered tracking markers are biologically active. 
72 hours post transfection, Gaussia Luciferase Assay on HEK293 cell lysate showed a 70.3-fold (VSVG-GFP-gLuc) 
and 90.4-fold (VSVG-RFP-gLuc) increase in gLuc activity compared to the negative control (A). The assay was run in 
triplicate with corresponding statistical significance (*) indicated (A). Images of HEK293 cells containing VSVG-
reporter-puro construct were taken 24 hours post 5 µg/ml puromycin treatment (B). Most cells were attached indicating 
biologically active protein cargo (B). Puromycin treatment of untransfected HEK293 cells (not shown) resulted in cell 
death within 24 hours. Images were taken at 10x magnification using fluorescent microscopy.   
 
 
Harvest and Characterization of Modified Exosomes 
 
Modified exosomes from producer HEK293 cells were harvested from cell media for further 
characterization. To reduce the necessity for transient transfection of VSVG-reporter-puro 
constructs into producer cells, stable cell lines were established as shown in Figure 5. The 
characteristic punctuated morphology of exosomes was seen in both VSVG-GFP-puro and VSVG-
RFP-puro modified cells (Fig. 5A) under the fluorescent microscope 40 days (GFP) or 20 days 
(RFP) post 5 µg/mL puromycin treatment. Images of Hoechst stained stable cell lines were taken 
on a confocal microscope 72 days (GFP) or 56 days (RFP) after treatment, respectively. As seen in 
Figure 5B the modified exosomes were still expressed.  
 
  
	
Figure 5. Intracellular localization of modified exosomes in stable cell line. 
Puromycin treatment of 5 µg/mL was utilized to establish a stable cell line. (A) Images of VSVG-GFP-puro (Day 40) 
	A	 					 	 	 		B	
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and VSVG-RFP-puro (Day 20) stable cell lines were taken at 20x magnification on a fluorescent microscope. (B) 
Stable cell lines were HOECHST stained. Images were taken on Day 56 (RFP) and Day 72 (GFP). Confocal 
microscope at 40x magnification was used. 
 
ELISA against CD63 exosome marker was performed to quantify the harvested exosomes.  All four 
harvests yielded on average 9x109 exosomes/mg, which was in the same range as the number 
unmodified control exosomes (Fig 6A). Next, nanoparticle tracking analysis (NTA) was performed 
to characterize size distribution of the harvested exosome. All constructs had a mode between 64 – 
69 (± 1.2 – 10.1) nm which was comparable to the size of control exosomes 70 ± 3.5 nm (Fig 6B). 
The results indicated that the modification of exosomes did not disturb the size distribution of the 
exosomes. All modified and control exosomes were also compared to the standard nanoparticle size 
of 100 nm (Fig. 6B). To check the cargo activity in harvested exosomes, Gaussia luciferase assay 
was performed. It was confirmed that luciferase enzyme within the exosomes was still biologically 
active shown by an activity increase in both VSVG-GFP-gLuc and VSVG-RFP-gLuc constructs 
compared to unmodified control exosomes (Fig. 6C). There was a statistically significant increase 
of 310 and 910 fold, respectively. The presence of GFP and RFP reporters was confirmed using 
confocal microscopy. As shown in Figure 6D, all four types of modified exosomes were GFP or 
RFP positive compared to unmodified control exosomes. Finally, a Western Blot was performed to 
detect exosomal marker CD63 within the modified exosomes. The results indicated the presence of 
glycosylated CD63 at 40 kDa in all 3 tested constructs (Fig. 6E).   
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 6. Characteristics of engineered exosomes released from the producing cells. 
Engineered exosomes were purified from cell serum-free Ultra-Culture media (Gibco). Exosomes were then precipitated 
from the solution using ExoQuick-TC (SBI). (A) The amount of exosomes per milligram of protein was quantified using 
ELISA and antibody against CD63 exosome marker. All VSVG constructs had on average 9x109 exosomes/mg which is 
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comparable to unmodified exosome number (control). (B) Exosome size and distribution was analyzed using NTA 
(Particle Characterization Laboratories, Inc. Novato) and compared to unlabeled (standard) and CD63 labelled (control) 
exosomes. All VSVG modified exosomes showed a size distribution range of 45-193 nm with corresponding modes 
shown. (C) Biological activity of loaded cargo was tested with Gaussia luciferase assay on purified exosomes. VSVG-
GFP-gluc exosomes showed 310 x increase and VSVG-RFP-gLuc showed 910 x increase in enzymatic activity compared 
to unmodified exosomes (control). (D) Purified exosomes were observed under confocal microscope at 40 x 
magnification (white bar corresponds to 10 µm) (E)  Western Blot on lysed exosomes was performed to detect exosomal 
markers CD63 (and CD9 if we perform it). In all 3 tested constructs, chemiluminescence showed a band at approximately 
40 kDa, which corresponds to glycosylated CD63 protein.  
 
Exosomes Uptake by Host Cells  
 
An uptake assay was performed to demonstrate that the harvested modified exosomes could be 
endocytosed by different mammalian cells. The time course tracking of exosomes showed their 
uptake at the edges of the cell at a 6h time point (Fig. 7) Then, the exosomes moved to paranucleus 
where they stayed until the final 48h time point (Fig. 7). The uptake was tested in 3 human cell 
lines (HEK293, Hep-G2, U87) and a mouse cell line (L929) (Fig. 7), all of which showed a 
successful uptake and similar distribution mechanism. The results indicate that the modification on 
exosomes does not hinder their natural ability to be used as a delivery vesicle.   
 
 
	
	 	 	 	 		 
         
 
 
 
 
	
	
Figure 7. Protein-loaded exosomes can be effectively taken up by mammalian cells. 
An uptake assay in four different cell lines (HEK293, U87, HepG2, L929) was performed using modified exosomes in 
serum-free Ultra-Culture media (Gibco). 6 hours post assay, VSVG-GFP-puro loaded exosomes were taken up as seen 
in the punctuated morphology on the edges of the cells (white arrows). 24 and 48 hours post assay, exosomes moved to 
the paranuclear space and remained at the location. Images were taken on a fluorescent microscope at 20x 
magnification (HEK293, U87, HepG2) or on a confocal microscope at 40x magnification (L929).  
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Lysosomal and Endosomal Colocalization of Modified Exosomes  
 
After confirming that the modified exosomes could be uptaken by different cell lines, we tested if 
the exosomes co-localize with lysosomal and endosomal compartments. Endosomal and lysosomal 
staining was done on recipient cells after an exosome uptake. As Figure 8 shows, after overlaying 
the image of VSVG-GFP-puro construct with either endosomal or lysosomal RFP stain, there were 
many overlapping areas (yellow) that indicated colocalization of the modified exosomes with 
endosomes and lysosomes in HEK293 (Fig. 8A) and U87 (Fig. 8B) cells. The insets show enlarged 
overlay areas to further imply the location of the constructs in the compartments. Hoechst stain on 
U87 cells was performed to emphasize the nucleus (Fig. 8B).  
 
 
 
Figure 8. Lysosomal and endosomal staining of exosome host cells. 
48 h after VSVG-GFP-puro exosome uptake, either HEK293 (A) or U87 (B) cells were stained using LysoTracker Red 
DND-99 (Invitrogen) lysosomal stain or CellLight Early Endosome-RFP (Invitrogen) endosomal stain as indicated. 
Cells stained for lysosome were incubated at 37°C with 5% CO2  for 30 min whereas cell stained for endosomes were 
incubated for 16 hours under the same conditions. Overlaid images and insets show yellow colocalized areas where 
VSVG-GFP-puro is implied to be in the compartments. Confocal images were taken at 40 x magnification. White bars 
correspond to 10 µm.  
 
 
Biological Activity of the Cargo in the Host Cells  
 
Finally, we tested biological activity of the cargo after cell uptake. For VSVG-reporter-puro 
construct, a cell counting assay was done 48 hours after puromycin treatment to determine the 
number of live cells. As data show, there were more live cells in the well with puro modified 
exosomes (50 %) compared to the gLuc (35 %) modified control well (Fig. 9A). Both wells were 
then compared to a control well that did not undergo puromycin treatment. The data gained from 
the counting assay was supported by the images taken before treatment and 48 hours after treatment 
(Fig. 9B). For VSVG-reporter-gLuc construct, the enzymatic activity increased with time in cells 
that underwent uptake treatment with VSVG-reporter-gLuc modified exosomes (data not shown). 
After 48 hours, this activity decreased. 
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Figure 9. Biological activity of puromycin resistant protein after exosome uptake. 
VSVG-GFP-cargo modified exosomes were added into HEK293 cells. After 48 hours, cell counting was done on the 
gLuc and puro groups. The percentages of live cells in the gLuc group was 35% and puro group 50% both compared to 
a control that was not treated with puromycin (A). Images were taken prior as well as 24 h (data not shown) and 48 h 
(B) after 3µg/ml puromycin treatment. Images show that most cells in the gLuc group were dead whereas puro group 
still had some live cells attached. Images were taken on a florescent microscope at phase setting.  
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3.2 Discussion  
 
Although there are many approaches for delivery of therapeutic proteins into lysosomes, all of 
them have limitations including immunogenicity, low bioavailability, or inability to cross blood 
brain barrier.1,2 
 
To overcome the limitations, we have combined nanoparticle technology to deliver proteins by 
designing four vectors for a VSVG transmembrane protein fused with fluorescent and activity 
reporter proteins. The design was created to deliver biologically active reporters into naturally 
produced nanoscale exosomes by using the VSVG as an anchor. The modified vesicles were then 
delivered into lysosomes of recipient cells. The results were validated through multiple 
experiments and reported in this study.  
 
Transfection of the vectors into HEK293 cells showed successful loading of each construct onto 
endosomes as demonstrated by the punctuated morphology of the images taken up to 72 hours 
post transfection. The morphology was tracked at three different time points and did not show any 
significant differences at each point. A co-transfection of designed vectors with exosomal 
markers, either XPACK or CD63, demonstrated that the constructs truly go into the endosomal 
compartment. An overlay of the RFP reporter from the designed construct with the GFP from the 
exosome marker was indicated by a yellow color. The data demonstrated that the constructs were 
localized within the endosomal compartment as MVB.  
 
Next, we showed that the gLuc reporter protein retained its biological activity in a cell lysate in 
both GFP and RFP constructs. That indicated that the expression and loading process likely did 
not hinder the activity of the reporter. The same was observed for the puromycin resistant reporter 
as the cells containing the VSVG-reporter-puro constructs showed resistance to puromycin 
treatment.   
 
The characterization of exosomes was done in five-fold. First, ELISA against exosome marker 
CD63 demonstrated that the amount of harvested exosomes per milligram of proteins for all four 
constructs was in the same range as the amount of harvested unmodified exosomes. That showed 
that exosome modification did not alter the exosome harvest yield. Next, nanoparticle tracking 
analysis (NTA) showed that the particle size and distribution of exosomes was in the same range 
as unmodified exosomes, which demonstrated that our modification did not change or vary the 
size distribution of the exosomes. Third, activity assay on harvested gLuc modified exosomes 
showed retained activity of the cargo in both the RFP and GFP constructs. That indicated that the 
cargo could not only be successfully loaded but it could also keep the biological activity. Confocal 
images of harvested exosomes were then taken to visually confirm presence of RFP and GFP 
reporters in exosomes. The images showed the typical punctuated morphology in all constructs. 
Lastly, a Western Blot confirmed the presence of exosome marker CD63 in all three tested 
constructs, further confirming the presence of exosomes.  
 
In the following step, we showed that our modified exosomes were successfully taken up by three 
different human cell lines as well as a murine cell line. In all cases, the recipient cells started to 
show the presence of exosomes as soon as 6 hours post uptake assay. The data indicated both that 
the modified exosomes were able to be expressed and harvested, and that they could be 
endocytosed by recipient cells.  
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The goal of this work was to deliver the modified exosomes into lysosomes for a potential protein 
replacement therapy. Chemical staining of lysosomes after exosome uptake by two different 
recipient cells indicated a partial overlay of the exosomes and lysosomes. Biological staining of 
endosomes showed the same partial overlay of the two compartments indicating a co-localization. 
Uptaken exosomes become a part of endosomal pathway that can lead to either loading into 
lysosomes or fusion with plasma membrane,9,10 which can explain the partial and not full overlay 
with lysosome.  
 
After showing that the modified exosomes could be taken up by recipient cells and directed to 
lysosomal compartment through the endosomal pathway, we performed an activity assay on the 
recipient cells. A cell counting assay on the puromycin treated host cells demonstrated that the 
puro-modified exosomes had a slightly higher number of live cells indicating the biological 
activity of the cargo. For gLuc cargo, the luciferase activity increased until 48 hours post exosome 
uptake, demonstrating a presence of biologically active Gaussia luciferase.  
 
In this work, we have engineered fused proteins that load therapeutics into exosomes. The 
modified exosomes can then be analyzed for activity once released into the media. Upon 
harvesting, the exosomes can be taken up by recipient cells and directed to a lysosomal 
compartment while retaining the biological activity of the cargo. For future work, we plan to 
exchange gLuc for a protein that replaces a missing enzyme in a specific lysosomal storage 
disease.    
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CONCLUSION 
 
To address current challenges with delivery of bioactive proteins into lysosomes, we first designed 
vectors using VSVG transmembrane protein to deliver cargos into exosomes. We used GFP or 
RFP as visual reporters, and gLuc or puro as cargos. The constructs were successfully tracked in 
exosomes co-localized with XPACK and CD63 markers in HEK293 cells. Additionally, the 
producer cells showed significant biological activity. Extraction and characterization of exosomes 
indicated that the modification using the engineered constructs did not alter the characteristics of 
exosomes such as size and yield. Moreover, the engineered exosomes retained the ability to be 
endocytosed by recipient cells. Finally, we showed that the engineered exosomes not only co-
localized with lysosomal and endosomal compartments but the loaded cargo was still biologically 
active in the recipient cells. The ability to engineer exosomes containing biologically active cargos 
allows for application in drug delivery into lysosomes.  
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